An approach to QSAR of 16-substituted pregnenolones as microsomal enzyme inducers

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 21, Issue 1, 1996, Pages 7-11

  Rekka, E A ^a   Kourounakis, P N ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

16 substituted pregnenolones; Electrostatic potential; Microsomal enzyme induction; QSAR

Indexed keywords

DIGITOXIN; DRUG METABOLIZING ENZYME; ETHYLMORPHINE; INDOMETACIN; MICROSOME ENZYME; PREGNENOLONE; PREGNENOLONE DERIVATIVE; ZOXAZOLAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; ELECTRICITY; ENZYME INDUCTION; FEMALE; LIPOPHILICITY; MOLECULAR SIZE; NONHUMAN; ORAL DRUG ADMINISTRATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT;

EID: 0030017278     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03190271     Document Type: Article

References (11)

1. Gonzales F.J., Gelboin H.V. (1993) : Role of human cytochrome P-450s in risk assessment and susceptibility to environmentally based disease. J. Toxicol. Environ. Health, 40, 289-308.
2. Lewis D F.V., Moereels H., Lake B.G., Ioannides C., Parke D.V. (1994) : Molecular modeling of enzymes and receptors involved in carcinogenesis: QSARs and COMPACT-3D. Drug Metab. Rev., 26, 261-285.
3. Wright M.C., Paine A.J. (1994) : Induction of the cytochrome P450 3A subfamily in rat livers correlates with the binding of inducers to a microsomal protein. Biochem. Biophys. Res. Commun., 201, 973-979.
4. Shimada T, Guengerich F.P. (1985) : Participation of rat liver cytochrome P-450 induced by pregnenolone-16α-carbonitrile and other compounds in the 4-hydroxylation of mephenytoin. Mol Pharmacol., 28, 215-219.
5. Kourounakis P.N., Rekka E. (1990) : Structural considerations of the 16-cyano and related pregnenolones on their drug metabolic inducing activity Eur J. Med. Chem., 25, 701-704.
6. Kourounakis P.N., Rekka E., Demopoulos V.J , Retsas S. (1991) : Effect of the position of the cyano-group of cyanopregnenolones on their drug metabolic inducing activity. Eur J Drug Metab. Pharmacokinet., 16, 15-19.
7. Rekker R F., Mannhold R. (1992) : In Rekker R.F., Mannhold R. (Eds). Calculation of Drug Lipophilicity, The Hydrophobic Fragmental Constant Approach. Weinheim. VCH, pp 82-84.
8. Martin Y.C (1978) : Calculation of the physical properties of compounds In: Grunewald G.L (Ed) Quantitative Drug Design. New York, Marcel Dekker, pp. 62-114.
9. Tute M.S. (1990) : History and objectives of quantitative drug design. In: Hansch C., Sammes P.G., Taylor J.B., Ramsden C A. (Eds). Comprehensive Medicinal Chemistry, vol. 4. Oxford, Pergamon Press, pp 1-31.
10. Verloop A., Hoogenstraaten, Tipker J. (1976) : Development and application of new steric parameters in drug design. In: Ariëns E.J. (Ed.). Drug Design, vol VII. New York, Academic Press, pp. 165-207.
11. McFarland J.W., Gans D.J. (1990) : Linear discriminant analysis and cluster significance analysis. In: Hansch C., Sammes P.G., Taylor J.B , Ramsden C.A. (Eds). Comprehensive Medicinal Chemistry, vol. 4. Oxford, Pergamon Press, pp. 667-689.